---
title: "FDA prüft Zulassungsantrag für Sangamos Gentherapie bei Fabry-Krankheit"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274710426.md"
description: "Sangamo Therapeutics Inc. has initiated a rolling submission of a Biologics License Application (BLA) to the FDA for its gene therapy product Isaralgagene civaparvovec (ST-920) aimed at treating Fabry disease. The FDA has agreed to use data from the completed Phase 1/2 STAAR study as the primary basis for approval, with the mean annualized eGFR slope after 52 weeks serving as an intermediate clinical endpoint."
datetime: "2026-02-03T21:08:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274710426.md)
  - [en](https://longbridge.com/en/news/274710426.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274710426.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274710426.md) | [繁體中文](https://longbridge.com/zh-HK/news/274710426.md)


# FDA prüft Zulassungsantrag für Sangamos Gentherapie bei Fabry-Krankheit

Sangamo Therapeutics Inc. hat mit der rollierenden Einreichung eines Biologics License Application (BLA) bei der US-amerikanischen Food and Drug Administration (FDA) im Rahmen des Accelerated Approval Programms für das Gentherapieprodukt Isaralgagene civaparvovec (ST-920) zur Behandlung der Fabry-Krankheit begonnen. Die FDA hat zugestimmt, dass die Daten aus der abgeschlossenen Phase 1⁄2 STAAR-Studie als primäre Grundlage für die Zulassung verwendet werden können, wobei der mittlere annualisierte eGFR-Slope nach 52 Wochen als intermediärer klinischer Endpunkt dient. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief on February 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Sangamo Therapeutics, Inc. (SGMO.US)](https://longbridge.com/en/quote/SGMO.US.md)

## Related News & Research

- [FDA official says UniQure fell short on Huntington's trial, defends new study request](https://longbridge.com/en/news/277874344.md)
- [Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting | IRD Stock News](https://longbridge.com/en/news/277220357.md)
- [Bioventus beats Q4 revenue estimates on strong demand for pain treatments and surgical solutions](https://longbridge.com/en/news/277932436.md)
- [UniQure slides after FDA says trial data insufficient for brain disorder therapy filing](https://longbridge.com/en/news/277472558.md)
- [Veeva Systems Q4 revenue eases past estimates](https://longbridge.com/en/news/277834275.md)